Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure

Circulation

Volumn 93, Issue 12, 1996, Pages 2128-2134

  Massie, Barry M ^b,c   Fisher, Susan G ^a   Deedwania, Prakash C ^b,c   Singh, Bramah N ^d   Fletcher, Ross D ^e   Singh, Steven N ^e  

^a Dept Vet Aff Coop Studs Prog ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amiodarone; cardiomyopathy; heart failure; morbidity; prognosis

Indexed keywords

AMIODARONE; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEALTH STATUS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RADIOISOTOPE VENTRICULOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0029938356     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.12.2128     Document Type: Article

References (29)

1. Cleland JG, Dargie HJ, Findlay IN, Wilson JT. Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients with heart failure. Br Heart J. 1987;57: 436-445.
2. Hamer AW, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cardiol. 1989;14:1768-1774.
3. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet. 1994;344:493-498.
4. Pratt CM, Eaton CM, Francis M, Woolbert S, Mahmarian J, Roberts R, Young JB. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J. 1989;118:433-440.
5. Stevenson WG. Mechanisms and management of arrhythmias in heart failure. Curr Opin Cardiol. 1995;10:274-281.
6. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern Med. 1994;121:529-535.
7. Chatterjee K. Amiodarone in chronic heart failure. J Am Coll Cardiol. 1989;14:1755-1756. Editorial.
8. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995;333:77-82.
9. Singh S, Fletcher RD, Fisher S, Deedwania P, Lewis D, Massie B, Singh B, Colling CL. Congestive heart failure: survival trial of antiarrhythmic therapy (CHF-STAT). Control Clin Trials. 1992;13: 339-350.
10. Ross J Jr. Afterload mismatch and preload reserve: a conceptual framework for the analysis of ventricular function. Prog Cardiovasc Dis. 1976;18:255-264.
11. Grogan M, Smith HC, Gersh BT, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;69: 1570-1573.
12. Brignole M, Gianfranchi L, Menozzi C, Bottoni N, Bollini R, Lolli G, Oddone D, Gaggioli G. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol. 1994;74:242-246.
13. Freedman M, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol. 1991;31:1061-1069.
14. Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med. 1995;122:689-700.
15. Gottlieb SS, Riggio DW, Lauria S, Peters RW, Shorofsky SR, Cines M, Froman D, Gold MR. High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. J Am Coll Cardiol. 1994;23:560-564.
16. Eichhorn EJ. The paradox of beta-adrenergic blockade for the management of congestive heart failure. Am J Med. 1992;92: 527-538.
17. Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol. 1994;23:814-821.
18. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
19. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642.
20. CIBIS Investigators. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
21. Packer M. Results of the Prospective Randomized Amlodipine Survival Evaluation (PRAISE) trial. Presentation at American College of Cardiology Scientific Meeting, April 1995.
22. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M, and PROFILE Investigators and Coordinators. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation. 1993;88(suppl I):I-301. Abstract.
23. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468-1475.
24. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors: RADIANCE study. N Engl J Med. 1993;329:1-7.
25. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
26. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR. β-Blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:2426-2441.
27. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 1994;23:943-950.
28. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind, randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
29. Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin ML, Packer M, Murphy BE, Neuberg GW, Steingart RM, Levine TB, DeHaan H. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Circulation. 1993;88:492-501.